Details of the Drug Reposition

General Information of This Drug (ID: DM82Z30)

• Drug Name: Topiramate (DM82Z30)
• Synonyms: Epitoma; Epitomax; TOR; Tipiramate; Tipiramato; Topamac; Topamax; Topimax; Topina; Topiramato; Topiramatum; Topomax; Cilag brandof topiramate; Janssen brand of topiramate; Ortho brand of topiramate; Tipiramate [French]; Tipiramato [Spanish]; Topamax Sprinkle; Topiramate tablet; Topiramatum [Latin]; Topiramic acid; McN 4853; RWJ 17021; KS-1122; KW-6485; McN-4853; RWJ-17021; Topamax (TN); Topamax, Topiramate; Topiramate (TPM); Topiramate / Placebo; Topiramato [INN-Spanish]; Topiramatum [INN-Latin]; USL-255; RWJ-17021-000; Topiramate [USAN:BAN:INN]; Topiramate (JAN/USAN/INN); Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate; Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI);Beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate; [(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate; 2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate; 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-(beta)-D-fructopyranose sulfamate; 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate; 5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, beta
• Therapeutic Class: Anticonvulsants
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

6 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Epilepsy with generalized tonic-clonic seizures	DISMG0FL	N.A.	Approved	[1]
Obesity	DIS47Y1K	5B81	Approved	[1]
Hyperlipidemia	DIS61J3S	5C80.Z	Approved	[1]
Hypertriglyceridemia	DIS7SN6U	5C80.1	Approved	[1]
Alcohol dependence	DIS4ZSCO	6C40.2	Approved	[2]
Epilepsy	DISBB28L	8A60-8A68	Approved	[2]

1 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
LennoxGastaut syndrome	DISOTGO5	8A62.1	Discontinued in Phase 2	[3]

1 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Metabolic syndrome x	DISU8N7X	5C50-5D2Z	Investigative	[1]

References

• [1] Topiramate FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6849).
• [3] Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia